The pharmacokinetic and pharmacodynamic profiles of
penbutolol were examined in healthy volunteers and in
cancer patients using a pharmacokinetic/pharmacodynamic (pk/pd) model. After receiving a 40 mg single oral dose of
penbutolol, the absorption rate constant, apparent volume of distribution and serum clearance of
penbutolol were found to be reduced in the
cancer group. Changes in the disposition of the conjugate metabolite were also observed in the
cancer patients.
Penbutolol unbound fraction in serum was statistically decreased (p < 0.005) in the
cancer group, according to the increase in the serum levels of
alpha 1-acid glycoprotein seen in that group (p < 0.05). The pharmacodynamic effect of
penbutolol was measured as the reduction in heart rate (HR); in healthy volunteers, a linear relationship (p < 0.01) between effect and
penbutolol serum concentrations (total or unbound) was found. In contrast, in
cancer patients, values of HR did not vary statistically in respect to baseline values. These results show that in
cancer patients, a change in the pharmacokinetics of
penbutolol occurs (associated with changes in
drug protein binding), together with an alteration in the pharmacodynamics.